Skip to main content
. 2021 Feb 12;34(3):945–951. doi: 10.1007/s13577-021-00500-8

Fig. 3.

Fig. 3

Elevated CTCs in patients with lymph node or distal metastatic sites. a CTCs counts in patients with (lymph node MS) or without (local) lymph node metastasis. b CTCs counts in patients with (distal MS) or without (local) distant metastasis. c ROC analysis of CTCs counts and serum biomarkers for evaluating metastasis risk